By Esther Onyegbula

A United Kingdom-based healthcare innovator, MedBioTech, has advocated a shift towards home-based healthcare and preventive diagnostics, saying the future of medicine lies in making healthcare more accessible, patient-centred and driven by early disease detection.

The company’s co-founder, Mrs. Oluwadamilola Janet Olatunde, said that healthcare systems across the world have evolved significantly since the COVID-19 pandemic, with increasing emphasis on delivering care beyond hospitals.

According to her, the pandemic exposed major gaps in healthcare delivery, particularly delays in testing, diagnosis and routine health monitoring, prompting the establishment of MedBioTech to address those challenges.

She said the company’s vision is anchored on bringing healthcare services directly to patients through innovative diagnostic solutions.
“With our guiding principle of bringing healthcare to people’s doorsteps, we are building a model that complements existing healthcare systems while expanding access to essential diagnostic services,” Mrs. Oluwadamilola Janet Olatunde said.

She identified In Vitro Diagnostics (IVD) as one of the most important components of modern healthcare, describing it as critical to disease detection, monitoring and overall patient management.

According to her, IVD testing, which involves analysing biological samples such as blood, urine and saliva, has become indispensable in supporting clinical decision-making and improving healthcare outcomes.
“IVD enables early and precise detection of diseases, supports continuous monitoring, enhances efficiency in healthcare delivery, and provides reliable data for informed medical decisions,” she stated.

Mrs. Oluwadamilola Janet Olatunde noted that the increasing global demand for efficient healthcare services has made diagnostic technologies more important than ever, adding that IVD would continue to play a vital role in building sustainable and data-driven healthcare systems.

She disclosed that MedBioTech is expanding access to diagnostic services through home-based testing, mobile sample collection and community-focused healthcare delivery, aimed at reaching patients outside conventional hospital settings.

Operating in both the United Kingdom and Nigeria, she said the company is working to bridge existing gaps in diagnostic accessibility while responding to changing patient needs and lifestyles.

The MedBioTech co-founder also underscored the importance of preventive healthcare, noting that early diagnosis and proactive health management remain key to reducing pressure on healthcare systems.

She explained that wider access to diagnostic services enables timely medical intervention, improves long-term health outcomes and encourages greater patient awareness and participation in healthcare decisions.

“Our approach supports a shift from reactive to preventive care, ensuring that individuals and healthcare providers can address potential health concerns before they become critical,” she said.

Mrs. Oluwadamilola Janet Olatunde reaffirmed the company’s commitment to advancing an integrated, patient-focused healthcare system through innovation and expanded diagnostic services.

She expressed optimism that MedBioTech’s continued expansion into key markets, including Nigeria, would contribute to improving healthcare accessibility and strengthening preventive care.

“The future of healthcare is being shaped by innovation and powered by diagnostics. It is no longer confined to hospitals but delivered wherever it is needed most,” she added.